Acellmed among the finalists of this year’s EEC Start-up Challenge!

Nearly 150 applications were submitted to the prestigious Start-up Challenge 2022 competition, organized within the framework of 14th European Economic Congress. As a result, the most interesting start-ups, divided into five contest categories, were selected. The best 15, who qualified for the semi-finals, presented their work to a broad audience during the European Economic Congress,…

Read More

ACELLMED ON AN ECONOMIC MISSION TO ITALY

For the second time Acellmed as one of the companies from the Silesia region has been selected and qualified to participate in a foreign trade mission. This time we will present our company in Italy between 9th and 13th of May 2022. The mission is organized under the project “Economic promotion of the region and…

Read More

Acellmed against COVID-19: researchers step up the fight against the pandemic

We are proud to announce that the consortium Acellmed – Silesian Park of Medical Technology – University of Wroclaw received funding in “The Competition for the development of innovative therapeutic solutions using RNA technology” (ABM/2021/5), organized by the Medical Research Agency Our project, entitled “Mutation-resistant nanotherapeutics inhibiting infection progress of RNA-virus, SARS-CoV-2” received the highest…

Read More

SARS-CoV-2 Tests

  • SARS-CoV-2 Test Met. Real Time RT-PCR (English language) – Sale!
  • SARS-CoV-2 Rapid RT-PCR test Coyote BioscienceCo (English language) – result up to 3 hours!
  • SARS-CoV-2 Rapid RT-PCR test Coyote BioscienceCo – result up to 3 hours!
  • SARS-CoV-2 test, antigen (English language) – Sale!
  • SARS-CoV-2 Test Met. Real Time RT-PCR
  • SARS-CoV-2 Test Met. Real Time RT-PCR
  • IgG/IgM – SARS-CoV-2 boxed tests

Our aim:

Acellmed is a start-up founded in 2019 as a response to regional and global market demand for implementing innovative pharmaceutical and biotechnology solutions. We are focused on developing medicinal products that provide optimal efficiency and safety. We have access to modern research and scientific background. We work with ambitious scientists and operate on the basis of a modern and refined business model. Our goal is to bring to market innovative and effective solutions in the field of pharmacy and medical biotechnology – especially solutions based on microRNA technology, stem cells and liposome drug carriers (nanotechnology). Acellmed addresses its offer to leading representatives of Big Pharma, R&D units and biotechnology companies from Poland and abroad.

The therapeutic preparation for corneal reconstruction using 3D bioprinting technology

The innovative treatment for personalized liposome-based therapy of acute myeloid leukemia, acute myeloblastic leukemia using small inhibitory RNAs

Stem cells (iPSCs) and corneal stem cells

The therapy for use in the treatment of infections caused by SARS-CoV-2 virus

Commercial research

One of the principal reasons to suspend ongoing research on new therapies is their cardiotoxicity. Regulations require that novel, and promising therapeutic molecules shall be subjected to the rigoristic toxicity tests using traditional methods in vitro and referential animal models. Those tests, however, do not reflect the reaction of human organism on drugs fully; also, they do not allow on detection of many potentially cardiotoxic substances. Direct application of drugs onto human cardiomyocytes, on the one hand, limits the use of lab animals; on the other – it creates a unique opportunity to select and test proper medications correcting particular cardiomyocytes defects. Directly-applied drugs are, therefore, the base of personalized medicine.

 

Moreover, Acellmed is developing a technology of “the heart-on-the chip,” based on the use of miniaturized micro-circulation systems which will allow on investigating the interaction between different heart cell types, and in the future – also of other organs.

Production line of iPSC and cardiomyocytes

In its research, Acellmed uses human peripheral blood cells (leucocytes), which effectively reprograms into iPSC; afterward, with high efficiency differentiates them into heart cells – cardiomyocytes. Hence we create iPSC bank cells from patients suffering from heart diseases (e.g., genetic primary and secondary cardiomyopathy) and healthy individuals.

Preparation in the field of regenerative medicine, in the form of a treatment using corneal limbus stem cells together with a transparent fibrin scaffold used to perform the procedure of corneal reconstruction for patients with lesions of various etiologies. The application of the preparation assumes autologous transplantation of cells taken from an individual patient and multiplied under laboratory conditions, which will then be applied to a biodegradable fibrin scaffold prepared in 3D technology.
abm-znaki

As a part of current strategic activities related to the development of an innovative offer, Acellmed is focused on the development of a unique solution being an original nanotherapeutic with no analogue product on the world market so far, that would be effective against SARS-CoV-2 infection and inhibition of COVID-19 disease progression. To date, no similar approach has been found for the formula of an antiviral drug dedicated to the SARS-CoV-2 coronavirus. This furmula may prove to be as effective as or superior to mixtures of human or humanized monoclonal antibodies. The drug significantly reduces the mutational variability of human ACE2, while an approach that includes peptides with a sequence identical to fragments of the ACE2 protein provides no future resistance to the drug.

The actions will be conducted on the basis of microRNAs used in oncology therapy – which is currently a global trend in the field of oncology treatment. The aim will be to create a new unique nanomolecular product – based on RNA inhibitor drugs directed specifically to leukemic cells (blasts) characterized by the presence of specific markers. Depending on the characteristics of each type of acute myeloid leukemia (AML), it will be possible to use one or a mixture of preparations used in monotherapy or combined therapy with reduced doses of cytostatics or other drugs inhibiting the progression of the disease.

Our customers

Business

  • Biotechnology, pharmaceutical and cosmetics

Science

  • Scientists interested in research on IPSC and cells differentiated from iPSC

Healthcare

  • Health care providers / health care institutions

Our offer

Products

  • Complete line of iPSC and cardiomyocytes
  • Conducting complete of generating iPSC and differentiated cel upon the commission of potential researchers interested in thier application

Research services

  • Research on the safety and effectiveness of potential drugs: comprehensive studies on the toxicity of selected substances – potential oncological drugs
  • Tests on drug efficacy in correcting cardiomyocytes defects, caused by functional disorder (as a result of mutations or undergoing oncological therapy)

Research on the safety and effectiveness of potenial drugs:

  • We offer the industry and health care institutions the toxicity studies, including tests on potential cardiotoxicity of the substances suspected to be an environmental threat

Our offer will enable the scientists and companies researching new drugs, on selecting safer substances, reducing unnecessary costs of preclinical trials; it may accelerate the process of introducing new drugs into the market.

Contact

    I consent to processing of my personal data contained in the above contact form by Acellmed Ltd. with the registered seat in Zabrze, St. M. Curie-Skłodowskiej 10C, 41-800 Zabrze, to contact in connection with the application sent via the contact form. The consent may be withdrawn at any time without affecting the lawfulness of personal data processing, which was made on the basis of the consent granted before its withdrawal.

    The controller of the personal data, i.e. the entity deciding on the purposes and methods of their processing, is Acellmed Ltd. with the registered seat in Zabrze (41-800), St. Marii Curie - Skłodowskiej 10c, hereinafter referred to as "Acellmed". The contact details of the data protection officer are: iod@acellmed.pl.


    Privacy policy - more

    Adres

    ACELLMED Sp. z o. o.
    St. M. Curie-Skłodowskiej 10c
    41-800 Zabrze
    biuro@acellmed.pl